

# FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Pfizer
Enrollment	119 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Part 1 only: Adult participants between 18 to 55 years of age, inclusive, at the time of signing the ICD
- Part 2 only: Adult participants, who at the time of screening, are between the ages of 18 and 70 years, inclusive.
- Part 1 only: Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital sign assessments, temperature, 12-lead ECGs, laboratory tests
- BMI of 17.5 to 40 kg/m<sup>2</sup>; and a total body weight >50 kg (110 lbs)
- Part 2 only: Must meet the following AD criteria:  
... and 5 more (see full listing online)

### Exclusion (12)

- Have a history of systemic infection requiring hospitalization and parenteral antimicrobial therapy, any lymphoproliferative disorder, malignancies.
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, immunological/rheumatological disorder.
- Have undergone significant trauma or major surgery within 1 month of the first dose of study intervention.
- Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by both of the following:
  - A positive QuantiFERON-TB Gold In-tube or equivalent test.
- ... and 7 more (see full listing online)

## Locations (2 total)

---

Anaheim Clinical Trials, LLC, Anaheim, California, United States  
Miami Dermatology and Laser Research, Miami, Florida, United States